Raymond James & Associates Has $4.01 Million Position in Smith & Nephew plc (NYSE:SNN)

Raymond James & Associates lifted its stake in Smith & Nephew plc (NYSE:SNN) by 172.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 128,854 shares of the medical equipment provider’s stock after purchasing an additional 81,500 shares during the period. Raymond James & Associates’ holdings in Smith & Nephew were worth $4,013,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also modified their holdings of the company. Mather Group LLC. increased its holdings in shares of Smith & Nephew by 9,735.3% in the second quarter. Mather Group LLC. now owns 1,672 shares of the medical equipment provider’s stock valued at $42,000 after purchasing an additional 1,655 shares in the last quarter. Allspring Global Investments Holdings LLC grew its holdings in Smith & Nephew by 1,894.3% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 1,735 shares of the medical equipment provider’s stock worth $43,000 after acquiring an additional 1,648 shares during the period. EverSource Wealth Advisors LLC grew its holdings in Smith & Nephew by 92.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,454 shares of the medical equipment provider’s stock worth $61,000 after acquiring an additional 1,179 shares during the period. GAMMA Investing LLC grew its holdings in Smith & Nephew by 160.0% during the 3rd quarter. GAMMA Investing LLC now owns 2,257 shares of the medical equipment provider’s stock worth $70,000 after acquiring an additional 1,389 shares during the period. Finally, Headlands Technologies LLC grew its holdings in Smith & Nephew by 225.0% during the 1st quarter. Headlands Technologies LLC now owns 3,851 shares of the medical equipment provider’s stock worth $98,000 after acquiring an additional 2,666 shares during the period. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analysts Set New Price Targets

SNN has been the subject of a number of analyst reports. Deutsche Bank Aktiengesellschaft lowered shares of Smith & Nephew from a “buy” rating to a “hold” rating in a report on Friday. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a report on Monday, August 5th. Two equities research analysts have rated the stock with a hold rating, two have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy”.

Smith & Nephew Price Performance

Shares of NYSE SNN opened at $25.24 on Friday. The company’s fifty day moving average is $29.98 and its 200-day moving average is $27.81. Smith & Nephew plc has a twelve month low of $23.24 and a twelve month high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11.

Smith & Nephew Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.